Niacin extended-release/simvastatin

Area of Science:

• Cardiovascular Pharmacology
• Lipid Metabolism Disorders

Background:

• Niacin extended-release (ER)/simvastatin is a fixed-dose combination targeting lipid management.
• Simvastatin is an HMG-CoA reductase inhibitor, while niacin is a B-complex vitamin.

Purpose of the Study:

• To evaluate the efficacy and tolerability of niacin ER/simvastatin in patients with dyslipidemia.
• To compare the lipid-lowering effects of niacin ER/simvastatin with simvastatin monotherapy.

Main Methods:

• Two randomized controlled trials (SEACOAST I and II) were conducted.
• Patients received varying doses of niacin ER/simvastatin or simvastatin monotherapy for 24 weeks.
• Lipid profiles, including non-HDL-C, LDL-C, HDL-C, and triglycerides, were assessed.

Main Results:

• Niacin ER/simvastatin significantly reduced non-HDL-C and triglycerides compared to simvastatin monotherapy.
• HDL-C levels increased more with the combination therapy.
• LDL-C reduction was comparable in SEACOAST I, but noninferiority was not met in SEACOAST II.
• Flushing was the most frequent adverse event.

Conclusions:

• Niacin ER/simvastatin demonstrates superior efficacy in reducing non-HDL-C and triglycerides compared to simvastatin alone.
• The combination therapy positively impacts HDL-C levels.
• The safety profile is generally acceptable, with flushing being manageable.